---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-046121"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:31:32.934612+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Natera Q1 revenue $501.8M (+36.5% YoY); positive cash flow $23.2M

## Summary
- Total revenue $501.8M (+36.5% YoY); product revenue $500.0M (+37.1%).
- Gross margin 63.1% (up from 56.7%); tests processed 855,100 (+16.2%).
- Net loss $66.9M ($0.50 EPS) improved from $67.6M ($0.56) in prior year.
- Positive operating cash flow $23.2M; cash & investments $991.6M.
- Oncology test volume 167,700 (+46.1% YoY); CEO cites record Signatera growth.

## SEC filing metadata
- accession: 0001104659-25-046121
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465925046121/0001104659-25-046121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465925046121/tm2513945d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-046121
- JSON: https://secwatch.observer/filing/0001104659-25-046121.json
- Plain text: https://secwatch.observer/filing/0001104659-25-046121.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.